CPHI Excellence in Pharma Award Winners 2022

CPHI Frankfurt 2022 1 - 3 November, 2022, Frankfurt am Main, Germany.
CPHI Frankfurt announces the winners of the prestigious 2022 CPHI Pharma Awards, recognising outstanding achievements from the global pharma industry, across 10 specialist categories.

The CPHI Pharma Awards recognise progress and innovation across the pharma supply chain. This year's winners are:

CEO of the Year - Manni Kantipudi, Aragen

API Development - Tokuyama Corporation

Finished Formulation - Accord Healthcare

Manufacturing Technology and Equipment - Just-Evotec Biologics

Pharmaceutical Packaging & Drug Delivery - Evonik

Supply Chain, Logistics, and Distribution - HCL Technologies

Regulatory Procedures and Compliance - Lonza Capsules and Health Ingredients

Digital Innovation - ATMPS

Sustainability - Indaver

Innovation in Response to COVID-19 - Moderna

Manni Kantipudi, CEO of Aragen was chosen by the judges as the clear winner of CEO of the Year, one of the most coveted prizes, for delivering outstanding performance with sustained growth and robust strategies. The company has undergone a number of impressive facility improvements, investment rounds and double-digit growth.

Moderna's development of its SPIKEVAX mRNA-based vaccine received the special award for Innovation in Response to COVID-19 category. The messenger RNA (mRNA) technology used in Moderna’s COVID-19 vaccine is based on more than a decade of research and, having received emergency authorization in 70 countries, more than 807 million doses of the vaccine were shipped globally in 2021.

In the API Development category, the Tokuyama Corporation was chosen for its novel synthesis of sodium dependent glucose co-transporters (SGLT2), used in the treatment of diabetes. Previous synthetic methods suffer from need for cryogenic conditions (-78oC), which significantly restricted the supply of this important class of drugs. The Tokuyama Corporation addressed this challenge by developing a new synthetic method which can be undertaken under very mild conditions (40oC).

Accord Healthcare was selected as the winner in the Finished Formulation category for the development of its Sixmo®, a subcutaneous buprenorphine (BPN) implant, the first of its kind, for the treatment of opioid dependence.

In the Manufacturing Technology and Equipment category, the Just-Evotec Biologicsentry was awarded the top prize for its innovative JPOD®. This is a small-footprint, highly automated cGMP manufacturing facility that leverages single-use systems and reconfigurable cleanroom pods for maximum flexibility. J.POD® can operate clinical or commercial processes in semi- or fully continuous mode with 500-1000L bioreactors.

Evonik is the Pharmaceutical Packaging & Drug Delivery award winner, for its polymeric nucleic acid delivery systems. Developed in conjunction with Stanford University these comprise a new class of polymers that complement existing lipid nanoparticle-based delivery technologies. The system allows a library of CARTs (charge-altering releasable transporters) to be developed that target different organs, have different bioactivities, and can accommodate different types of biomolecules.

In the Supply Chain, Logistics and Distribution category HCL Technologies was bestowed the award for its Intelligent Asset Tracking Management (IATM) Consignment Inventory Management system for medical devices, consumables, surgical items and kits. This provides E2E visibility with logs and timestamps from the consignor's manufacturing facility through to the point of care using First Expired First Out (FEFO) inventory methodology. Working in real-time means it improves auditing and inventory reconciliation as well as reducing risk of using an expired product for a medical procedure.

Lonza Capsules and Health Ingredients was judged to be the winner in the Regulatory Procedures and Compliance category for its Capsugel® titanium dioxide (TiO2)-free white gelatin capsule. This novel opacifying technology leverages the functionality of crystalized salts to provide the same whiteness and masking as capsules containing TiO2. The new capsule will fulfil the evolving demand of its customers to meet new titanium dioxide-free requirements for foods in the European Union.

Haatali, the world's first and only blockchain-based vein-to-vein tracking platform for advanced therapies, enabled ATMPS to win the Digital Innovation category. This patented technology provides a much-needed platform for the tracking and real-world delivery of labour intensive cell and gene therapies (which currently often use paper records) to be scaled-up, reducing healthcare burdens and increasing patients access to therapies. The interoperable systems will be transformative for the delivery of the dozens of new therapy approvals expected in the next few years,

In the Sustainability category, Indaver was the clear winner for its Inda-MP - a specialized facility for the recovery of precious metals from liquid waste streams. Homogeneous precious metal catalysts are increasingly used in API and fine chemical production and typically end up in liquid waste streams, so efficient recovery is paramount to reducing environmental impact. Inda-MP fulfils this need by offering a circular, one-stop solution, from shipment of the liquid waste until delivery of the refined precious metals.

About CPHI

CPHI is the leading global community for pharmaceutical professionals, hosting a portfolio of digital and in-person connection opportunities across the whole pharma supply chain. Evolving our events to become part of an integrated digital package means the industry has more time, more flexibility and more opportunities to meet, learn and connect. CPHI is the world's primary pharma event series, with the largest community, and our goal is to proactively inspire the pharma industry to create purposeful partnerships.

At the Heart of Pharma: connecting people and businesses from all over the world. At the heart of pharma, we act as catalysts for industry developments

For more information, please visit www.informamarkets.com

CPHI Frankfurt (1 - 3 November 2022 at Messe Frankfurt, Frankfurt); CPHI & P-MEC India (29 November - 1st December 2022 at the India Expo Mart, Greater Noida, Delhi NCR - Delhi, India); CPHI China (20-22 December 2022 at SNIEC - Shanghai, China); Pharmapack Europe (1 - 2 Feb, 2023 at Paris Expo, Porte de Versailles - Hall 7.2, Paris); CPHI Japan (19 - 21 April, 2023 at the Big Sight Exhibition Centre - Tokyo, Japan); CPHI North America (25 - 27 April, 2023 at Pennsylvania Convention Center, United States).

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...